Acme Solar has reported a 77% year-on-year drop in net profit to INR 122 crore for the fourth quarter ended March 31, 2025. The developer’s total income for the quarter, however, rose to INR 539.25 crore, up 69.5% year-on-year from INR 318 crore in Q4 FY 2024.
For the full fiscal year ended March 31, 2025, total income stood at INR 1,575 crore, 7.4% up from INR 1,466 crore in FY 2024. Net profit dropped to INR 250.8 crore from INR 697.7 crore in FY 2024.
FY 2025 marked significant capacity addition for the developer as it commissioned 1.2 GW of solar projects during the year. Additional 165 MW solar capacity was commissioned in May 2025, taking the cumulative operational capacity to 2,705 MW—101.9% up from 1,340 MW as of March 31, 2024.
With 1,900 MW projects won during the year, the company now has a total contracted portfolio of 6,970 MW. The projects won include 1 GW FDRE, 600 MW solar and 300 MW hybrid capacities. Moreover, the company signed power purchase agreements for 1,890 MW (1,590 MW FDRE and 300 MW hybrid capacities) during the year.
This content is protected by copyright and may not be reused. If you want to cooperate with us and would like to reuse some of our content, please contact: editors@pv-magazine.com.
By submitting this form you agree to pv magazine using your data for the purposes of publishing your comment.
Your personal data will only be disclosed or otherwise transmitted to third parties for the purposes of spam filtering or if this is necessary for technical maintenance of the website. Any other transfer to third parties will not take place unless this is justified on the basis of applicable data protection regulations or if pv magazine is legally obliged to do so.
You may revoke this consent at any time with effect for the future, in which case your personal data will be deleted immediately. Otherwise, your data will be deleted if pv magazine has processed your request or the purpose of data storage is fulfilled.
Further information on data privacy can be found in our Data Protection Policy.